Jenna Brager, PhD, RN, MS
Vice President of Drug Development
Jenna Brager, PhD, RN, MS, joined MyMD Pharmaceuticals® as the Director of Regulatory Affairs effective May 2021. Prior to joining MyMD, Dr. Brager served as the Director of Clinical Research and Scientific Grants for LifeBridge Health, a community health system consisting of 5 specialty centers – Sinai Hospital, Northwest Hospital, Carroll Hospital, Levindale Hospital, and Grace Medical Center (formally Bon Secours Baltimore Hospital).
During this time, she revised and implemented over 20 policies and procedures guiding the execution and continuation of 250+ research trials (Phase I-IV) to ensure regulatory standards and compliance were upheld. Additionally, Dr. Brager led the Convalescent Plasma Program, where she took a primary role in spearheading a new initiative to provide FDA-approved emergency treatment for COVID-19 patients under the MAYO EAP resulting in transfusing of close to 300 patients.
She also supported the Research and Innovation teams to deploy a mobile health application program called GetWell Loop, developed with a Bethesda, Maryland company called GetWell Network. This mHealth platform supported over 8,400 patients who were treated through our drive-through COVID testing locations. The platform allowed her team to respond to patient messages and alerts on this digital platform about COVID symptoms and quarantining guidelines, at a time when guidance was quickly changing.
Prior to her role with LifeBridge Health, Dr. Brager spent four years at Johns Hopkins Hospital working with clinicians and researchers to promote the integration of substance-use related content including screening, brief intervention, and referral to treatment (SBIRT) into the nursing curricula at Johns Hopkins School of Nursing. Additionally, she worked with HIV researchers to help beta test the design and implementation of a mobile health app to link HIV-positive individuals to patient care navigators. Lastly and most impactfully, Dr. Brager worked with MyMD’s Chief Scientific Officer, Adam Kaplin to execute clinical trials funded by Janssen to combat treatment-resistant depression using intranasal esketamine.
Dr. Brager has also served as an assistant editor for conferences by AMIA MedInfo and HiMMS, as well as a scientific reviewer for the Journal of Child Abnormal Psychology and the Journal of Comprehensive Psychiatry. Additionally, she previously served as the Secretary for the Southern Nurses Research Society. She has also authored and co-authored numerous articles and reviews.
Dr. Brager received her B.S. in Nursing from the University of North Florida, graduating cum laude and received her Ph.D. from the Johns Hopkins University School of Nursing. Additionally, she received a B.S and MS in Sport Administration from the University of Miami (Florida).
- British Society of Immunology, Liverpool, UK December 5-8, 2022
- Journal of Drug Research
Pharmacology and clinical profile of MYMD-1® (isomyosamine), an oral, selective, next-generation, TNF-alpha inhibitor that crosses the blood brain barrier
Jenna Brager, Ronald Christopher, Adam Kaplin, Chris Chapman
A Double-blind, Placebo-controlled, Randomized, Single Ascending, and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose of MYMD1™ Capsules in Healthy Male and Female Adult Subjects
Citation: Brager J, Chapman C, Dunn L, Kaplin A. A Double-blind, Placebo-controlled, Randomized, Single Ascending, and Multiple Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose Isomyosamine Capsules in Healthy Adult Subjects. Drug Res (Stuttg). 2022 Nov 11. doi: 10.1055/a-1962-6834. Epub ahead of print. PMID: 36368677.